Organization (Industry)
Jazz Pharmaceuticals plc
ClinicalTrials.gov lists Jazz Pharmaceuticals plc as lead sponsor of 206 trials. It has 186 active development programs and 53 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 18 registered with a 2026 start date. The hollow diamonds on the dashed line are a forecast of the full-year count, planned starts included: about 14 in 2026 and about 11 in 2027, the average of the 24 months through September, counted as registered and carried forward. The columns, the lighter one included, count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. This method has not been backtested on organizations. In backtests on conditions with as many trial starts a year as this organization (5 to 20), forecasts made part-way through the year were typically off by about 28 percent and ran about 20 percent low against the count later registered; forecasts made before the year began were off by about 39 percent and ran about 37 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored. The 2026 forecast is below the 18 already registered with a 2026 start date: at the cutoff, 7 trials were already registered to start in October to December, more than the method's monthly average allows for, and the method does not use those planned starts. 1 trial is registered to start in 2027 or later.
This page covers Jazz Pharmaceuticals plc: 206 lead-sponsored trials and 6 legal-entity registrations.
Disease areas (160)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Leukemia, Myeloid, Acute | 33 |
| Epilepsy | 26 |
| Disorders of Excessive Somnolence | 24 |
| Pain | 22 |
| Narcolepsy | 17 |
Showing 5 of 160 disease areas.
Trials by start year as sponsor or collaborator (27)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 1 trial is registered to start in 2027 or later, and not listed here.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 18 |
| 2025 | 10 |
| 2024 | 5 |
| 2023 | 21 |
| 2022 | 13 |
| 2021 | 23 |
| 2020 | 20 |
| 2019 | 17 |
| 2018 | 11 |
| 2017 | 9 |
Showing 10 of 27 years.
Prediction, not a registry value: median of 36 months from start to primary completion across 14 trials still running at the 2026-10-09 snapshot; registered median of 20 months across 162 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (186)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Zanidatamab | Stomach Neoplasms | Phase 3 | 5 |
| Zanidatamab | Head and Neck Neoplasms | Phase 3 | 4 |
| Zanidatamab | Esophageal Neoplasms | Phase 3 | 4 |
| Cannabidiol | Seizures | Phase 3 | 5 |
| Dordaviprone (ONC201) | Glioma | Phase 3 | 4 |
Showing 5 of 186 active programs.
Approved assets (53)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Sativex | 36 |
| Cannabidiol | 21 |
| Xyrem | 6 |
| JZP-258 | 3 |
| JZP258 | 2 |
Showing 5 of 53 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 38% hit target (n=79) | 36% on time (n=69) |
Journals published in (145)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Sleep | 14 |
| Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine | 12 |
| Blood | 10 |
| Sleep medicine | 10 |
| Bone marrow transplantation | 9 |
Showing 5 of 145 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 31 | 4 | 2024-12-10 |
SEC-reported annual financials (11)
Shown in this order: newest fiscal year first; SEC EDGAR XBRL companyfacts, USD as reported.
| Fiscal year | Revenue (USD) | Net income (USD) | R&D (USD) |
|---|---|---|---|
| 2025 | 4,267,586,000 | -356,148,000 | 782,736,000 |
| 2024 | 4,068,950,000 | 560,120,000 | 884,000,000 |
| 2023 | 3,834,204,000 | 414,832,000 | 849,658,000 |
| 2022 | 3,659,374,000 | -224,060,000 | 590,453,000 |
| 2021 | 3,094,238,000 | -329,668,000 | 505,748,000 |
| 2020 | 2,363,567,000 | 238,616,000 | 335,375,000 |
| 2019 | 2,161,761,000 | 523,367,000 | 299,726,000 |
| 2018 | 1,890,922,000 | 447,098,000 | 226,616,000 |
| 2017 | 1,618,693,000 | 487,848,000 | 198,442,000 |
| 2016 | 1,487,973,000 | 396,831,000 | 162,297,000 |
Showing 10 of 11 fiscal years.
Financing and grant events (29)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2025-10-21 | Royalty / licensing | 90,000,000 | Sec extracted |
| 2025-04-21 | Other financing | not disclosed | Sec extracted |
| 2025-03-04 | Other financing | not disclosed | Sec extracted |
| 2024-11-26 | Debt financing | not disclosed | Sec extracted |
| 2024-09-06 | Debt financing | 981,000,000 | Sec extracted |
Showing 5 of 29 events.
Climate targets, as filed (1)
| Reporting year | Net-zero target |
|---|---|
| 2025 | not disclosed |
Workforce and board diversity, as filed (1)
| Reporting year | Workforce % women | Board % women |
|---|---|---|
| 2025 | not disclosed | not disclosed |
Organization relationships (100)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| University of California System | Co sponsors trial with | 7 |
| Government of the United States of America | Co sponsors trial with | 6 |
| Jazz Pharmaceuticals Ireland Limited | Co sponsors trial with | 5 |
| Oncoceutics (United States) | Co sponsors trial with | 4 |
| Weill Medical College of Cornell University | Co sponsors trial with | 4 |
Showing 5 of 100 relationships.
Latest dated events (346)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2027-01-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-12-31 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-12-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-12 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-11-30 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 346 events.
Biomarker capability evidence (799)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| A1CF | Trial sponsor | Primary endpoint in a Phase 3 trial |
| ABCD1 | Trial collaborator | Named in trial inclusion criteria |
| ABL1 | Trial sponsor | Named in trial inclusion criteria |
| ALB | Trial sponsor | Named in trial inclusion criteria |
| ALB | Trial collaborator | Named in trial inclusion criteria |
Showing 5 of 799 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, clia clinical laboratory certificates, and biomarkers this organization publishes on.